Completed PHASE3 INTERVENTIONAL 2-arm NCT00632008

Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers

A Randomised, Double-blind, Placebo-controlled Study to Determine the Efficacy of Soluble Beta-1,3/1,6-glucan in Chronic Foot Ulcers in Diabetes

Sponsor: Biotec Pharmacon ASA

Conditions Chronic Diabetic Foot Ulcers

Interventions Placebo comparator Soluble beta-glucan (SBG)

Updated 5 times since 2017 Last updated: Jan 25, 2010 Started: Mar 31, 2007 Primary completion: Aug 31, 2009 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Diabetic Foot Ulcers, this trial is completed. The trial is conducted by Biotec Pharmacon ASA and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biotec Pharmacon ASA

Data source: Biotec Pharmacon ASA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Belfast, United Kingdom , Blackburn, United Kingdom , Bournemouth, United Kingdom , Bristol, United Kingdom , Glasgow, United Kingdom , Leeds, United Kingdom , Leicester, United Kingdom , Manchester, United Kingdom , Newcastle, United Kingdom , Northampton, United Kingdom and 1 more location